United States

Rise of crisis pregnancy centers highlights shift in anti-abortion movement

The Supreme Court will hear arguments in a case involving faith-based pregnancy centers in New Jersey. The organization is hoping to block the state from investigating whether they misled women into believing the centers offered abortions. The case highlights an effort to crack down on so-called crisis pregnancy centers. https://www.pbs.org/newshour/show/rise-of-crisis-pregnancy-centers-highlights-shift-in-anti-abortion-movement
Read More

State Variations in the Role of the Reproductive Health Safety Net for Contraceptive Care Among Medicaid Enrollees

Medicaid is a major source of coverage for contraceptive care for millions of people. Many Medicaid patients rely on a range of safety net providers including Planned Parenthood clinics, community health centers, state and local health departments, and Indian Health Services for their contraceptive care. The composition of the safety net and the relative role of the different providers vary considerably from state to state.
Read More

Democratic U.S. Senators Raise Alarm Over Trump Administration Efforts to Restrict Mifepristone

U.S. Senators Mark R. Warner and Tim Kaine, a member of the Senate Health, Education, Labor and Pensions (HELP) Committee, (both D-VA) joined Senator Patty Murray (D-WA) and all of their Democratic Senate colleagues in sending a letter to U.S. Secretary of Health and Human Services (HHS) Robert F. Kennedy, Jr. and U.S. Food and Drug Administration (FDA) Commissioner Marty Makary expressing alarm over the Trump Administration's plans to reexamine the safety and effectiveness of mifepristone. Since 2000, mifepristone has been approved by the FDA as a safe and effective medication for abortion care and miscarriage management. The Administration’s basis…
Read More

Understanding the Trump Administration’s Negotiated Drug Prices for Medicare

The Centers for Medicare & Medicaid Services (CMS) has just announced the prices that the federal government negotiated for 15 high-cost drugs covered by Part D, Medicare’s prescription drug benefit program, including the popular diabetes and obesity drugs Ozempic and Wegovy. This brings to a close the second round of Medicare’s Drug Price Negotiation Program, which was created by the Inflation Reduction Act of 2022 under the Biden administration. These negotiated prices will take effect in Medicare in January 2027.
Read More

Lawmaker Will Introduce Federal Bill To Safely Discharge Patients In Labor

The bill from Rep. Robin Kelly, a Democrat from Illinois, would require clinical justification for discharging patients presenting with signs or symptoms of labor, an assessment of travel distance, a confirmed back-up hospital or birthing facility, verification that patients have reliable transportation, and documentation of patient understanding, Becker's Hospital Review reported.
Read More
No widgets found. Go to Widget page and add the widget in Offcanvas Sidebar Widget Area.